Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bumble Inc (BMBL) vs Eli Lilly And Co (LLY) Price & Performance

Bumble IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Bumble Inc vs Eli Lilly And Co — how do they compare? Bumble Inc trades at $2.63 (market cap $366.87M), while Eli Lilly And Co trades at $1,215 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 2943.8× Bumble Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.

BMBLLLY
Market Cap
$366.87M$1.08T
Sector
TechnologyHealth
52-Week High
$7.17$1.24K
52-Week Low
$2.70$639.43
Enterprise Value
$672.73M$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bumble Inc

Bumble (BMBL) trades at $2.62, down 4.03% on the day, reflecting ongoing investor concerns. The stock is in a bearish technical trend with negative earnings and declining revenue. Recent strategic shifts, including removing the women-first messaging rule and exploring a sale, aim to revive growth amid falling paying users. Valuation ratios like P/S of 0.38 and P/B of 0.71 appear low, but profitability remains weak with a net income margin of -57.96%.

The outlook is cautious; while cost controls and product changes could stabilize the business, persistent losses and competitive pressures pose significant risks. Analyst consensus is mixed with a $3.62 price target, but high institutional selling and bearish sentiment suggest limited near-term upside. Investors should weigh potential turnaround against execution risks and market skepticism.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY